Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1874-1881

  Kievit, W ^a   Bolster, M J ^a   van der Wilt, G J ^a   Bult, P ^a   Thunnissen, F B J M ^a   Meijer, J ^b   Strobbe, L J A ^a   Klinkenbijl, J H G ^b   Wobbes, T ^a   Adang, E M M ^a   Beex, L V A M ^a   Tjan Heijnen, V C G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Adjuvant therapy; Breast cancer; Cost effectiveness; Guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 28444486348     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi394     Document Type: Article

References (27)

1. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994; 30: 60-65.
2. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001; 27: 137-142.
3. Fisher ER, Swamidoss S, Lee CH et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42: 2025-2031.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
8. Bontenbal M, Nortier JW, Beex LV et al. Adjuvant systemic therapy for patients with resectable breast cancer: Guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology. Ned Tijdschr Geneeskd 2000; 144: 984-989.
9. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
10. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
11. Voogd AC, Louwman WJ, Coebergh JW, Vreugdenhil G. Impact of the new guidelines for adjuvant systemic treatment of breast cancer at hospital level. Ned Tijdschr Geneeskd 2000; 144: 1572-1574.
12. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Liss 1997.
13. Bames DM, Harris WH, Smith P. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74: 1445-1451.
14. Oostenbrink JB, Koopmanschap MA, Rutten FF. Handleiding voor Kostenonderzoek: Methoden en Richtlijnen voor Economische Evaluaties in de Gezondheidszorg. Amstelveen: College voor Zorgverzekeraars 2000.
15. Chapman RH, Stone PW, Sandberg EA et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000; 20: 451-467.
16. Rutten-van Mölken MP, van Busschbach JJ, Rutten FF. Van Kosten tot Effecten. Een Handleiding voor Evaluatiestudies in de Gezondheidszorg. Maarssen: Elsevier Gezondheidszorg 2000.
17. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19: 1103-1109.
18. Taylor D. Funding medicines for people with multiple sclerosis. BMJ 2001; 323: 1379-1380.
19. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
20. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111-116.
21. Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA 1995; 273: 142-148.
22. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press 1999.
23. Guadagnoli E, Shapiro CL, Weeks JC et al. The quality of care for treatment of early stage breast carcinoma: Is it consistent with national guidelines? Cancer 1998; 83: 302-309.
24. Martin M, Pienkowski T, Mackey J et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003; (Abstr 43).
25. Winer EP, Hudis C, Burnstein HJ et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
26. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
27. van Enckevort PJ, TenVergert EM, Schrantee S et al. Economic evaluations of systemic adjuvant breast cancer treatments: Methodological issues and a critical review. Crit Rev Oncol Hematol 1999; 32: 113-124.